Non Alcoholic Fatty Liver Disease in Rheumatoid Arthritis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2006 by Shaare Zedek Medical Center.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Shaare Zedek Medical Center
ClinicalTrials.gov Identifier:
NCT00394238
First received: October 29, 2006
Last updated: October 30, 2006
Last verified: July 2006

October 29, 2006
October 30, 2006
November 2006
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00394238 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Non Alcoholic Fatty Liver Disease in Rheumatoid Arthritis
Not Provided

Rheumatoid arthritis is a chronic inflammatory systemic disease. It has a worldwide distribution and can affect all age group. The peak incidence is between fourth and sixth decade. It is more prevalent in women, and it’s prevalence in the general population in North America is between 0.2-1.5%. The etiology of RA is unknown, although clusters of the disease in families and high concordance in mono-zydotic twins support genetic predisposition. The prevalence of fatty liver disease in patients with rheumatoid arthritis is currently unknown. We wish to study the link between the two conditions by performing a son graphic imaging of the liver in a cohort of RA patients. If indeed a high prevalence of NAFLD will be found in the RA patients, further support will be landed for the link between inflammation and fatty liver disease. These findings may also have implications regarding the management and follow up of RA patients.

The validity of sonographic imaging for detection of fatty liver diseases is currently accepted: On ultrasonographic, fatty infiltration of the liver produces a diffuse increase in echogenicity as compared with that of the kidneys. Ultrasonography has a sensitivity of 89% and a specificity of 93% in detecting steatosis and sensitivity and specificity of 77% and 89% respectively in detecting increase fibrosis.

In view of all the above data, we expected to find higher prevalence of fatty liver in the patients with higher inflammation markers compare with patients with lower markers.

Not Provided
Observational
Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Not Provided
Not Provided
Not Provided
Not Provided
Arthritis, Rheumatoid
Procedure: Ultrasonographic imaging
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
50
October 2008
Not Provided

Inclusion Criteria:

  • Rheumatoid arthritis

Exclusion Criteria:

  • Age below 18
Both
18 Years and older
No
Contact: Ornit Cohen, Msc 0507867234 bionet@017.net.il
Israel
 
NCT00394238
20174CTIL
Not Provided
Not Provided
Shaare Zedek Medical Center
Not Provided
Principal Investigator: Michal Mates, MD Shaare Zedek Medical Center Jerusalem
Shaare Zedek Medical Center
July 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP